News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Teva Pharmaceutical Industries Limited Announces Launch of Generic Prometrium® Capsules in the United States
March 2, 2012
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today the commercial launch of Progesterone Capsules, 100 & 200 mg, the AB-rated generic equivalent of Abbott Laboratories’ Prometrium® Capsules.
Twitter
LinkedIn
Facebook
Email
Print
Asia
Europe
MORE ON THIS TOPIC
China
China plans to transform biotech sector into $522B powerhouse by 2030
September 18, 2026
·
2 min read
·
Annalee Armstrong
Lung cancer
Summit, BioNTech, more headline WCLC with next-gen lung cancer drugs
September 14, 2026
·
4 min read
·
Gabrielle Masson
Manufacturing
Samsung Biologics inks $262M manufacturing deal with European pharma company
September 11, 2026
·
2 min read
·
Nick Paul Taylor
Manufacturing
Sandoz plans ‘vast and vertically integrated’ supply chain to support 100-biosimilar vision
September 9, 2026
·
2 min read
·
Nick Paul Taylor
